Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The 2009 swine-origin H1N1 influenza virus (swH1N1) provided an opportunity to study immune responses to a new influenza strain in the context of seasonal influenza vaccination. Our goals were: to assess whether analyzing multiple parameters of immune responsiveness to influenza has an advantage over evaluating hemagglutination inhibition (HAI) titer alone, to determine whether vaccination with the seasonal vaccine induced cross-reactive immunity to swH1N1 in some individuals, and to determine whether the immune response against swH1N1 is higher after infection than vaccination.
Antibody and T cell responses were studied in ten subjects who were first immunized with the 2009–2010 seasonal influenza subunit vaccine, then 6 weeks later with the swH1N1 monovalent subunit vaccine. The amount of antibody against native virus glycoproteins, overall avidity of these antibodies, and HAI titer were measured. T cells were evaluated for proliferation and IFNγ secretion in response to the vaccine in vitro. Individuals with influenza-like illness were also evaluated, adding a microplate neuraminidase inhibition (NAI) test.
The immune response to influenza was highly variable and immune parameters did not increase in parallel. The seasonal vaccine induced antibodies recognizing the pandemic virus in 50% of subjects. Antibody affinity and NAI activity to swH1N1 were higher after natural infection than vaccination.
The evaluation of several immune parameters gives a more complete measure of immune responsiveness to influenza infection or vaccination than the HAI test alone.
- Gibbs AJ, Armstrong JS, Downie JC. From where did the 2009 ‘swine-origin’ influenza A virus (H1N1) emerge? Virol J. 2009;6:e207. CrossRef
- Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197–201. CrossRef
- Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature. 2009;459:1122–5. CrossRef
- Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52. CrossRef
- Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328:357–60. CrossRef
- Gilbert GL, Cretikos MA, Hueston L, Doukas G, O'Toole B, Dwyer DE. Influenza A (H1N1) 2009 antibodies in residents of New South Wales, Australia, after the first pandemic wave in the 2009 southern hemisphere winter. PLoS ONE. 2010;5:e12562. CrossRef
- Ikonen N, Strengell M, Kinnunen L, Osterlund P, Pirhonen J, Broman M, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill. 2010;15(5):pii=19478.
- Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375:1100–8. CrossRef
- McCullers JA, Van De Velde L-A, Allison KJ, Branum KC, Webby RJ, Flynn PM. Recipients of vaccine against the 1976 “swine flu” have enhanced neutralization responses to the 2009 novel H1N1 influenza virus. Clin Infect Dis. 2010;50:1487–92. CrossRef
- Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, et al. Seroprevalence following the second wave of Pandemic 2009 H1N1 influenza in Pittsburgh, PA, USA. PLoS ONE. 2010;5:e11601. CrossRef
- Kumari K, Gulati S, Smith DF, Gulati U, Cummings RD, Air GM. Receptor binding specificity of recent human H3N2 influenza viruses. Virol J. 2007;4:42. CrossRef
- Gulati S, Smith DF, Air GM. Deletions of neuraminidase and resistance to oseltamivir may be a consequence of restricted receptor specificity in recent H3N2 influenza viruses. Virol J. 2009;6:22. CrossRef
- Subbarao EK, Kawaoka Y, Ryan-Poirier K, Clements ML, Murphy BR. Comparison of different approaches to measuring influenza A virus-specific hemagglutination inhibition antibodies in the presence of serum inhibitors. J Clin Microbiol. 1992;30:996–9.
- Gulati U, Keitel WA, Air GM. Increased antibodies against unfolded viral antigens in the elderly after influenza vaccination. Influenza Other Respir Viruses. 2007;1:147–56. CrossRef
- Feng J, Gulati U, Zhang X, Keitel WA, Thompson DM, James JA, et al. Antibody quantity versus quality after influenza vaccination. Vaccine. 2009;27:6358–62. CrossRef
- Couch RB, Kasel J. Influenza. In: Lennette EH, Lennette DA, Lenette ET, editors. Diagnostic Procedures for Viral, Rickettsial and Chlamydial Infections. 7th ed. Washington, D.C.: American Public Health Association; 1995. p. 431–46.
- Noah DL, Hill H, Hines D, White EL, Wolff MC. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clinical and vaccine immunology: CVI. 2009;16:558–66. CrossRef
- Aymard-Henry M, Coleman MT, Dowdle WR, Laver WG, Schild GC, Webster RG. Influenzavirus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ. 1973;48:199–202.
- Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982;31:417–27. CrossRef
- Cate TR, Rayford Y, Niño D, Winokur P, Brady R, Belshe R, et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010;28:2076–9. CrossRef
- Gulati U, Kumari K, Wu W, Keitel WA, Air GM. Amount and avidity of serum antibodies against native glycoproteins and denatured virus after repeated influenza whole-virus vaccination. Vaccine. 2005;23:1414–25. CrossRef
- Chi C-Y, Liu C-C, Lin C-C, Wang H-C, Cheng Y-T, Chang C-M, et al. Pre-existing antibody response against 2009 pandemic influenza H1N1 viruses in Taiwanese population. Clinical and vaccine immunology: CVI. 2010;17:1958–62. CrossRef
- Mak GC, Choy PWW, Lee WY, Wong AH, Ng KC, Lim W. Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong. J Med Virol. 2010;82:1809–15. CrossRef
- Richards KA, Topham D, Chaves FA, Sant AJ. Cutting edge: CD4 T cells generated from encounter with seasonal influenza viruses and vaccines have broad protein specificity and can directly recognize naturally generated epitopes derived from the live pandemic H1N1 virus. J Immunol. 2010;185:4998–5002. CrossRef
- Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA. 2009;106:20365–70. CrossRef
- Del Giudice G, Stittelaar KJ, van Amerongen G, Simon J, Osterhaus ADME, Stöhr K, et al. Seasonal influenza vaccine provides priming for A/H1N1 immunization. Sci Transl Med. 2009;1:12re1. CrossRef
- Min J-Y, Chen GL, Santos C, Lamirande EW, Matsuoka Y, Subbarao K. Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology. 2010;408:128–33. CrossRef
- Ellebedy AH, Ducatez MF, Duan S, Stigger-Rosser E, Rubrum AM, Govorkova EA, et al. Impact of prior seasonal influenza vaccination and infection on pandemic A(H1N1) influenza virus replication in ferrets. Vaccine. 2010. doi:10.1016/j.vaccine.2010.08.067.
- Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med. 2009;361:2405–13. CrossRef
- Talaat KR, Greenberg ME, Lai MH, Hartel GF, Wichems CH, Rockman S, et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis. 2010;202:1327–37. CrossRef
- Beigel JH, Voell J, Huang C-y, Burbelo PD, Lane HC. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis. 2009;200:501–9. CrossRef
- Hayden FG, Howard WA, Palkonyay L, Kieny MP. Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12–13 February 2009. Vaccine. 2009;27:4079–89. CrossRef
- Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus
Journal of Clinical Immunology
Volume 31, Issue 5 , pp 900-912
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Pandemic 2009 H1N1 influenza
- vaccine response
- T cells after infection
- Industry Sectors
- Author Affiliations
- 1. Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- 2. Immunobiology and Cancer Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK, 73104, USA
- 3. Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA